Gilbert Edward M
Division of Cardiology, University of Utah School of Medicine, Salt Lake City, Utah, USA.
Rev Cardiovasc Med. 2002;3 Suppl 3:S42-7.
There is a growing economic burden from the treatment of heart failure that accounts for more than 5% of total health care expenditures. Hospitalization contributes between 60% and 75% of this total expense. The addition of beta-blockers to conventional heart failure therapy results in a significant reduction in hospitalization. As a consequence, beta-blocker therapy in heart failure is very cost-effective and compares favorably to that of other generally accepted medical interventions
心力衰竭治疗带来的经济负担日益加重，其费用占医疗保健总支出的5%以上。住院费用占这一总费用的60%至75%。在传统心力衰竭治疗中添加β受体阻滞剂可显著减少住院次数。因此，心力衰竭的β受体阻滞剂治疗具有很高的成本效益，与其他普遍接受的医疗干预措施相比具有优势。
